Clinical Trial Update: Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update for Anitocabtagene-autoleucel in relapsed/refractory multiple myeloma; the study sponsored by Kite, A Gilead Company is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anitocabtagene Autoleucel (anitocabtagene autoleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: Relapsed and Refractory Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING